Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.52 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 2/20 | 0.44 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4982670 | 0.86 | NAAA (0.71) | NAAAKDM4A | |
| SCHEMBL88365 | 0.86 | NAAA (0.71) | NAAAKDM4A | |
| SCHEMBL11501497 | 0.84 | NAAA (0.49) | NAAACNR1CNR2GLSKDM4A | |
| SCHEMBL2843459 | 0.84 | NAAA (0.68) | NAAAKDM4A | |
| SCHEMBL4985814 | 0.84 | NAAA (0.68) | NAAAKDM4A | |
| Hydrochloric Acid SCHEMBL4933082 | 0.83 | NAAA (0.67) | NAAAKDM4A | |
| Hydrochloric Acid SCHEMBL4933073 | 0.83 | NAAA (0.67) | NAAAKDM4A | |
| SCHEMBL4986402 | 0.83 | NAAA (0.61) | NAAACNR1CNR2KDM4A | |
| SCHEMBL13944848 | 0.82 | NAAA (0.47) | NAAACNR1CNR2GLSKDM4A | |
| SCHEMBL23740245 | 0.80 | CNR1 (0.47) | NAAACNR1CNR2GLSKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468378-B2 | Substituted quinoline compounds | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7393958-B2 | Triamide-substituted heterobicyclic compounds | PFIZER, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7368573-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2007-04-26 | — | — | US | disclosed |
| EP-1716137-A1 | SUBSTITUTED QUINOLINE COMPOUNDS | Pfizer Products Incorporated (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | BERTINATO PETER | 2006-10-05 | — | — | US | disclosed |
| US-20050234099-A1 | Substituted quinoline compounds | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
| WO-2005080373-A1 | SUBSTITUTED QUINOLINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234099-A1 | Substituted quinoline compounds | APOB, APOL1, MTPN | NAAA 2732/4885CNR1 1317/4885CCR3 3705/4885 |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | APOB, MTPN, CTRB1 | NAAA 2148/4885CNR1 974/4885CCR3 3737/4885 |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | APOB, MTPN, CTRB1 | NAAA 2148/4885CNR1 974/4885CCR3 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.